Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Litchlab | Accelerating Next-Generation Vaccine Development with Integrated CDMO Solutions

As global demand for agile, high-quality vaccine development continues to surge, the role of Contract Development and Manufacturing Organizations (CDMOs) has never been more vital. With increasing emphasis on mRNA, DNA, recombinant protein, and viral vector-ba...

Litchlab | Advancing with Global CDMO Growth — Your Trusted Partner for Liposome-Based Drug Delivery

As the pharmaceutical landscape shifts toward increasingly complex therapies and innovative delivery platforms, the global CDMO market continues to grow at a remarkable pace. According to BCC Research, the CDMO sector is expected to surpass $190 billion by 202...

Litchlab | Empowering Precision — Your Trusted Partner for Custom Drug Development Services

[April 14, 2025] — Litchlab, a specialized Contract Development and Manufacturing Organization (CDMO), is proud to announce the expansion of its Custom Drug Development Services, offering flexible, scalable, and fully tailored solutions for pharmaceutical comp...

Litchlab Expands Its Small Molecule API CDMO Services to Accelerate Global Drug Development

[April 14, 2025] — Litchlab, a specialized CDMO dedicated to advanced drug delivery technologies and pharmaceutical raw materials, proudly announces the expansion of its Small Molecule Active Pharmaceutical Ingredient (API) R&D and GMP Manufacturing Platfo...

Litchlab Expands Comprehensive API Services to Accelerate Drug Development for Global Pharma Partners

[April 14, 2025] — Litchlab, a specialized Contract Development and Manufacturing Organization (CDMO), proudly announces the expansion of its Active Pharmaceutical Ingredient (API) services, offering an integrated solution for pharmaceutical innovators seeking...

Litchlab — Your Reliable CDMO Partner for API Development and GMP Manufacturing

As an integrated CDMO with proven expertise in drug delivery systems, Litchlab also provides end-to-end services for Active Pharmaceutical Ingredient (API) development and manufacturing, helping global pharmaceutical partners bridge the gap from early-stage di...

上一页 1 2 3 4 5 下一页